Biosensis: 肌萎縮側索硬化的生物標誌物

Biosensis: 肌萎縮側索硬化的生物標誌物

2021.07.09

 

本文轉載至原廠電子報:Biosenis  https://www.biosensis.com/

Biomarkers for Amyotrophic Lateral Sclerosis

 

 

 

 

 

 

 

Dear Researcher,

 

Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease that causes progressive muscle weakness through loss of upper and lower motor neurons. The disease is fatal. However, ALS shows considerable variability in clinical presentations and prognosis between patients. Therefore, there is an urgent need to identify biomarkers that would help with the diagnosis, prognosis and ultimately treatment of ALS. 

 

ALS Biomarker Characteristics

In their review, Kirk et al.,(2019) identify 6 attributes that are desirable in a biomarker: 

1.   Specificity to disease

2.   Reproducibility

3.   Appearance in the early stage of the disease

4.   Stability across the diurnal period

5.   Independence of dietary status and behaviour

6.   The biomarker should demonstrate a notable change as the disease progresses

 

Of the 37 ALS biomarkers described, creatinine kinase in blood and p75 neurotrophin receptor Extracellular domain (NGFR, p75ECD) in urine receive the highest score of 3.5 on a scale of 0 – 6. In contrast to creatinine kinase, urinary p75ECD increases as disease progresses, and is inversely correlated with the ALSFRS-R score (the ALS Functional Rating Scale – Revised is a validated instrument for monitoring the progression of disability in patients with ALS). p75ECD has also been shown to be diurnally stable Shepheard et al.,(2017) and is present in significantly higher concentrations in ALS patients compared to patients with other neurological diseases Jia et al.,(2017). These factors as well as the non-invasive method of obtaining a urinary sample make p75ECD an excellent biomarker for ALS prognosis.

 

 

Urine p75ECD Quantification and the Importance of Normalisation

Biosensis offers the only NGFR/p75ECD ELISA kit (BEK-2239) extensively validated for accurate quantification in human urine, with excellent inter-assay (7.9-10.9%), intra-batch (3.2-6.9%) and inter-batch precision (7.5-9.9%).

 

Assay accuracy demonstrated by the p75ECD Assay

Figure 1: Parallelism of six serially diluted human urine samples from healthy donors using BEK-2239

 

 

 

Urinary biomarker concentrations should be reported as a ratio to urinary creatinine, because water reabsorption in kidneys affects urinary solute concentrations. Therefore, urine p75ECD readings should be normalized against creatinine levels from the same urine sample. 

Biosensis offers a 96-well Creatinine (Urinary) Colorimetric Assay Kit (CRE-001) which is based on the Jaffe reaction. Reproducible and accurate data is obtained in less than an hour. 

 

Receive a 20% discount on the Biosensis Creatinine (Urinary) Colorimetric Assay Kit if purchased together with one of our ELISA kits in one transaction. To receive a quote, contact us at sales@biosensis.com. For more information about either kit email biospeak@biosensis.com.

 

Good luck with your research,

The Biosensis Team

 

 

 

 

Biosensis Pty Ltd

 

Our mailing address is:

 

 

 

 

 

 

back-Top
open-line

LINE 線上諮詢

亞旭-LINE-QRcode

掃瞄或手機直接點擊條碼

error: Content is protected !!